Now Available -
On-Line Ordering
Click Here to View and Order Our Special Offer
Call Us Free:
866.757.2284
Fax Us:
301-644-3937
"An Explanation of the Use of ActiPatch in Podiatry"
narrated by Lawrence Michaelis, MD, MS and William Van der Reis, MD.
View the Movie
for their patients.
ActiPatch resolves the swelling and inflammation associated with heel pain.
Allows you patients to return to their life style activities sooner and in comfort.
Each ActiPatch delivers a minimum of 720 hours of effective therapy.
We use the same Pulsed Electro Magnetic Field (PEMF) technology used in bone growth stimulators.
You already know PEMF works and you know it's safe.
ActiPatch delivers breakthrough technology
in a wearable patch.
ActiPatch is an affordable, wearable, patch that delivers a safe low-power Pulsed Electromagnetic Field (PEMF) to injured tissue. ActiPatch works locally and directly on the site of injury. The patient feels no pain or sensation from ActiPatch while it's working.
Clinically proven and drug-free treatments.
Over the last 20 years, the medical use of electromagnetic therapy has established an excellent record of safety and has been used by a variety of doctors on thousands of patients for the safe treatment of bone and soft tissue conditions ActiPatch received a 510k FDA clearance for use in the reduction of edema (swelling) following blepharoplasty - a facial plastic surgical procedure.
PEMF - The science behind ActiPatch
When soft tissue is damaged the cells leak fluid and cellular components break down while the cellular debris causes inflammation, swelling and pain. ActiPatch stabilizes the leaking cell membrane by, in effect, recharging the membrane. The pulsed energy delivered by ActiPatch drives out the edematous fluid along with by-products of the damaged tissue.
- ActiPatch causes a reduction in the swelling ('edema') and inflammation that occurs after tissue injury ' a true and beneficial acceleration in the inflammatory process which occurs in virtually all wounds and tissue injuries, and, which is, an integral component of normal healing.
- ActiPatch facilitates improved micro-vascular perfusion of damaged tissue. The result is faster clearing of edematous fluid, and more rapid elimination of noxious agents [nitrous oxide, histamine, etc.] that are released into the surrounding tissue following an injury.
- These mechanisms provide an environment in which cell-to-cell communication is re-established in the area of the injured tissue This provides a well demonstrated and significant overall improvement in the restorative and recovery process following injury.
- As a result of the above changes, a decrease in the pain associated with soft tissue injury often occurs.
 |
Injured soft tissue The body reacts to injury to prevent infection. The visible signs are redness, heat, and swelling of the soft tissue. This condition inhibits the tissue from a rapid recovery. |
Soft tissue with full recovery ActiPatch delivers PEMF to |
What Physicians have to say about ActiPatch
'I have been using ActiPatch for
approximately one year and
am impressed with the results. It reduces pain and edema
without medication. The amount of pain relief and
edema reduction is remarkable with ActiPatch. The ActiPatch
unit is a safe, low cost, small, portable and a narcotic-free device.'
'I have found that BioElectronics' new product ActiPatch usually resolves pain associated with heel pain conditions such as plantar fasciitis in as little as 2-3 days. The potential for ActiPatch in the treatment of inflammatory conditions such as heel pain and acute sports injuries is enormous. The PEMF technology is safe and has been used for years, but until now it has not been available in a patch that a patient can wear at home.'
Clinical Trial for Plantar Fasciitis brochure
Heel Pain Clinical Evaluation brochure
Participate in a Plantar Fasciitis Clinical Study
Clinical References:
Click on the links below to access supporting clinical evidence.
The Physics and Science Behind ActiPatch
Podiatry Studies
Independent White Paper by James Ricketti DPM
Clinical reference describing the use of PEMF in Podiatry.
Clinical Evaluation of Diapulse as Adjunctive Therapy following
Foot Surgery
Kaplan, Earl G., Weinstock, R. E. (1968), Journal of the American Podiatry Association, Vol 58 218-221 results
indicated that Diapulse therapy resulted in a significant reduction in the amount of postoperative edema, erythema and pain.
Exposure to Pulsed Magnetic Fields in the Treatment of Plantar Ulcers in
Leprosy Patients
A Pilot Randomized Double-Blind, Controlled Clinical Trial; Sarma, R., Subrahmanyam, S., Deenabandhu, A, Narendra Babu,
C. R., Madhivanthanan, S., Kesavaraj, N. (1997), Indian J Lepr. 1997 Jul-Sep;69(3):241-50. findings strongly suggest that exposure to
PMF causes a significantly more rapid healing of plantar ulcers in leprosy patients.
Comparison of Shortwave Diathermy And Pulsed Electromagnetic Energy In Treatment Of
Soft Tissue Injuries,
Wilson, D H (1974), Physiotherapy, 60, 10, 83-85. ) studied acute inversion injuries of the ankle; matched pairs were
allocated at random to two groups. The first group received continuous SWD and a base treatment of exercise and walking instruction;
the second received pulsed energy and the same base treatment. No control or placebo groups were used. The author indicated that a
prior comparison between an active and placebo pulsed treatments in a similar population had shown that pulsed short-wave diathermy
was effective in reducing pain and disability.
Treatment of soft-tissue injuries by pulsed (high frequency) electrical
energy
WILSON DH, British Medical Journal, 2(29: 269-270, Apr 1972 Continuous SWD was administered for 15-minute periods
within the hour, once daily. Pulsed energy was given for one hour daily. A noticeable difference between the two treatment regimens
lies in the total power delivered; continuous SWD resulted in 22 1/2 watt-hours energy being received while those on the pulsed
program received 15 watt-hours. Those receiving pulsed energy displayed greater improvement (82.8%) in terms of swelling, pain and
disability than those in the continuous SWD group (44.2%).
'Effect of Pulsed Radio Frequency Therapy on Edema in Ankle
Sprains:
A Multisite Double-Blind Clinical Study,' A.A. Pilla & L. Kloth, Second World Congress for Electricity and
Magnetism in Biology and Medicine, 8-13 June 1997, Bologna, Italy, p. 300. Results of this double-blind, placebo-controlled study
indicated that treatment with two 30-minute sessions of non-invasive pulsed radio frequency therapy is effective in significantly
decreasing the time required for edema reduction in patients suffering from lateral ankle sprains
Pulsed Non-Thermal, High Frequency Electromagnetic Energy (Diapulse) in
the Treatment of Grade I and Grade II Ankle Sprains
Pennington GM, Danley DL, et al (1993). Military Medicine 158(2): 101-104. US Army study demonstrated that pulsed
non-thermal high frequency electromagnetic radiations was highly effective in treating Grade I and II ankle sprains. The results
showed significant improvement in the reduction of swelling. In addition twice as many patients reported a reduction in pain with the
treatment as those on the placebo.
PEMF Studies
Low Energy High Frequency Pulsed Electromagnetic Therapy For Acute
Whiplash Injuries.
A Double Blind Randomized Controlled Study. Foley-Nolan, Moore, K. Codd, M., Barry, C., O'Connor, P., Coughian, RJ.,
Scandinavian Journal of Rehabilitation Medicine (1992); 24 (1): 51-59.
Effect of a 15 Watt Pulsed 27.12 MHz and a 2mW pulsed 3 MHz device on the
tensile strength of rat abdominal wounds
p23. Bentall, RHC, (1981a). , In: Proceedings of the 1st annual meeting of the Bioelectrical Repair and Growth Society,
November 9-11, Philadelphia, USA.
The Treatment Of Pressure Sores Using Pulsed Electromagnet Energy (PEME)
Physiotherapy
Seaborne D., Quirion-De Giradi C., Rosseau M., Rivest M., Lambert J., (1996), (Canada), 48, 131-7
A Portable Pulsed Electromagnetic Field (PEMF) Device To Enhance Healing Of
Recalcitrant Venous Ulcers:
A Double-Blind, Placebo, Stiller MJ, Grace H, Pak, j, Shupack, l, Thaler S, Clare Kenny and Lorrie Jondreau (1993)
British Journal of Dermatology 127,147-154.